ARUP Laboratories
500 Chipeta Way – Salt Lake City, UT 84108
(800)522-2787 - www.aruplab.com
Julio C. Delgado, M.D. M.S., Director of Laboratories

*****Example Report*****

Patient Age/Gender: Unknown Male
Printed: 22-Feb-17 10:49:59

Procedure	Result	Units	Ref Interval	Accession	Collected	Received	Reported/ Verified
Block ID	ABC123			17-053-104698	22-Feb-17 10:44:00	22-Feb-17 10:44:00	22-Feb-17 10:47:49
IDH1 and IDH2 Mutation Results	Detected f			17-053-104698	22-Feb-17 10:44:00	22-Feb-17 10:44:00	22-Feb-17 10:47:49
IDH1-2 FFPE Source	FFPE Tissue			17-053-104698	22-Feb-17 10:44:00	22-Feb-17 10:44:00	22-Feb-17 10:47:49

22-Feb-17 10:44:00 IDH1 and IDH2 Mutation Results:

A mutation in IDH2 exon 4 was detected: c.395G>A,p.R132H.

This result has been reviewed and approved by Anna Matynia, M.D.

22-Feb-17 10:44:00 IDH1 and IDH2 Mutation Results:
Test information: IDH1 and IDH2 Mutation Results

This test is designed to detect mutations in exon 4 of the IDH1 and IDH2 genes that are frequently present in gliomas and in a subset of cases of acute myeloid leukemia. IDH1/2 mutations in gliomas are generally associated with a better prognosis. In acute myeloid leukemia, the prognostic significance of IDH1 mutations is context dependent. IDH1 mutations appear to be associated with worse outcome in patients without FLT3-ITD mutations (see J Clin Oncol 2010. 28:3636 and Blood 2010. 116:2779). In acute myeloid leukemia patients with IDH2 abnormalities, IDH2 R140 mutations appear to be associated with better outcome while IDH2 R172 mutations appear associated with worse outcome (see Blood 2011. 118:409).

Methodology:
DNA is isolated from FFPE tissue, blood, or bone marrow. The DNA is amplified for IDH1 and IDH2 covering exon 4 of both genes including the important residues R132 (IDH1), R140 (IDH2) and R172 (IDH2). Sanger sequencing is then performed to detect mutations.

Limitations:
Mutations in other locations within the IDH1 and IDH2 genes or in other genes will not be detected. The limit of detection for this test is 20 percent mutant allele.

Results of this test must always be interpreted within the clinical context and with other relevant data, and should not be used alone for a diagnosis of malignancy. This test is not intended to detect minimal residual disease.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS